A Phase 2 Trial Combining Pembrolizumab and Palliative Radiation Therapy in Gastroesophageal Cancer to Augment Abscopal Immune Responses

A Phase 2 Trial Combining Pembrolizumab and Palliative Radiation Therapy in Gastroesophageal Cancer to Augment Abscopal Immune Responses

Purpose: Single agent PD-1 inhibitors have yielded durable responses in a minority of gastroesophageal cancers. Radiation therapy has been recognized to promote antitumor immune responses and may synergize with anti-PD-1 agents. We sought to evaluate if combining palliative radiation therapy with pe...

Full description

Bibliographic Details
Main Authors: Chao, J. (Author), Chen, H. (Author), Chen, Y.-J (Author), D'Apuzzo, M. (Author), Fakih, M. (Author), Frankel, P. (Author), He, T.-F (Author), Klempner, S.J (Author), Lee, P. (Author), Solomon, S. (Author), Tajon, M. (Author)
Format: Article
Language:English
Published: Elsevier Inc. 2022
Subjects:
abscopal effect
adenocarcinoma
adult
aged
Article
cancer growth
cancer palliative therapy
cancer radiotherapy
clinical article
colitis
constipation
diarrhea
drug withdrawal
enterocolitis
esophagus cancer
fatigue
female
gastroesophageal junction
human
immune response
immunocompetent cell
male
multiple cycle treatment
overall survival
pembrolizumab
phase 2 clinical trial
pneumonia
programmed death 1 ligand 1
progression free survival
pruritus
radiation field
rash
response evaluation criteria in solid tumors
squamous cell carcinoma
stomach cancer
thrombocytopenia
treatment indication
treatment response
tumor biopsy
very elderly
xerostomia
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items